Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States

INTRODUCTION: Despite currently available treatments for adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL), survival outcomes remain poor, highlighting the need for new therapeutic strategies. This study estimates the cost-effectiveness of KTE-X19 to treat adults with R/R ALL fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Bijal D., Smith, Nathaniel J., Feng, Chaoling, Jeyakumar, Sushanth, Castaigne, Jean-Gabriel, Faghmous, Imi, Masouleh, Behzad Kharabi, Malone, Daniel C., Bishop, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309154/
https://www.ncbi.nlm.nih.gov/pubmed/35727476
http://dx.doi.org/10.1007/s12325-022-02201-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309154/
https://www.ncbi.nlm.nih.gov/pubmed/35727476
http://dx.doi.org/10.1007/s12325-022-02201-6

Ejemplares similares